Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E16.54 EPS (ttm)5.68 Insider Own0.01% Shs Outstand2.77B Perf Week3.22%
Market Cap260.10B Forward P/E14.67 EPS next Y6.40 Insider Trans-39.69% Shs Float2.77B Perf Month0.62%
Income16.11B PEG3.41 EPS next Q1.45 Inst Own67.30% Short Float1.35% Perf Quarter-3.62%
Sales71.88B P/S3.62 EPS this Y18.50% Inst Trans-0.25% Short Ratio4.34 Perf Half Y-3.85%
Book/sh25.66 P/B3.66 EPS next Y3.78% ROA12.30% Target Price109.16 Perf Year-6.95%
Cash/sh12.26 P/C7.66 EPS next 5Y4.84% ROE22.60% 52W Range81.79 - 106.63 Perf YTD-8.19%
Dividend3.00 P/FCF46.55 EPS past 5Y5.30% ROI18.40% 52W High-11.91% Beta0.62
Dividend %3.19% Quick Ratio2.20 Sales past 5Y3.70% Gross Margin69.50% 52W Low14.84% ATR2.06
Employees126500 Current Ratio2.50 Sales Q/Q-52.70% Oper. Margin28.30% RSI (14)49.93 Volatility2.25% 1.91%
OptionableYes Debt/Eq0.27 EPS Q/Q-49.10% Profit Margin22.40% Rel Volume0.97 Prev Close93.17
ShortableYes LT Debt/Eq0.20 EarningsOct 13 BMO Payout49.40% Avg Volume8.59M Price93.93
Recom2.50 SMA201.00% SMA50-1.67% SMA200-4.69% Volume8,328,927 Change0.82%
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Apr-12-13Reiterated Deutsche Bank Buy $82 → $87
Mar-26-13Reiterated UBS Buy $81 → $87
Jan-11-13Reiterated UBS Buy $76 → $78
Jan-04-13Upgrade Deutsche Bank Hold → Buy $75 → $82
Nov-20-12Initiated Stifel Nicolaus Hold
Jul-18-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
Apr-18-12Reiterated UBS Buy $71 → $70
Oct-04-15 10:01AM  3 Rock-Solid Dividend Stocks You Can Buy Right Now at Motley Fool
Oct-01-15 09:20AM  Pfizer Raises 2015 Outlook on Hospira Acquisition, Shares Up
08:01AM  3 Biotechs That Play Well with Others at Motley Fool
Sep-30-15 04:09PM  Other Franchises of JNJs Pharmaceuticals Segment in 2Q15
03:08PM  Johnson & Johnsons Pharmaceuticals Segment Grows in 2Q15
12:18PM  Arrowheads HBV Trial Success Could Attract Buyers; Are Gilead Or Bristol-Myers Paying Attention?
10:09AM  Did Johnson & Johnsons Consumer Healthcare Segment Grow in 2Q15?
10:09AM  Johnson & Johnsons Segment Performance in 2Q15
06:28AM  More Companies Say Targets Are the Key to Diversity at The Wall Street Journal
04:07AM  More Companies Say Targets Are the Key to Diversity at The Wall Street Journal
Sep-29-15 05:15PM  The Street gets bullish: MCD, JNJ & GPRO
03:00PM  Bristol-Myers, J&J Upgraded On New Drug Prospects at Investor's Business Daily
02:24PM  Street Talk: JNJ, MCD & more
01:51PM  Johnson & Johnson's stock paces Dow gainers after analyst upgrade at MarketWatch
01:38PM  Why Consumer Sentiment Deteriorated Further
11:24AM  Analysts Love These Two Dividend Aristocrats but How Does the Smart Money Feel about Them? at Insider Monkey
10:37AM  Stocks Rise As Biotechs Bounce; Yahoo, Vertex, Biogen Climb at Investor's Business Daily
08:59AM  J&J, Biotech, McDonald's: What's Moving Markets
08:50AM  Yahoo PT Cut Despite Alibaba; McDonald's Upgraded at Investor's Business Daily
08:49AM  Johnson & Johnson (JNJ) Stock Climbs Following Analyst Upgrade at TheStreet
08:48AM  Johnson & Johnson Seen As 'Safe Haven' By These Experts
08:41AM  Did Eli Lilly Just Get a Leg Up on Johnson & Johnson? at Motley Fool
08:32AM  Morning Movers: Look At All the Pharma Upgrades! at
07:53AM  Early movers: YHOO, MCD, AAPL, MSFT, LLY & more at CNBC
Sep-28-15 05:33PM  What to buy on a biotech buying spree
05:18PM  JOHNSON & JOHNSON Files SEC form 8-K, Other Events
02:21PM  Patients To Benefit From Latest Tech Trends
02:02PM  Why Johnson & Johnsons Growth Fell in 2Q15
02:02PM  Johnson & Johnson Stock Remained Neutral to 2Q15 Earnings
01:00AM  Hip implant maker claims surgical funder inflated patients' bills
Sep-25-15 06:14PM  Johnson & Johnson Looks to IBM's Watson to Predict Patient Outcomes at The Wall Street Journal
04:45PM  Commodities are Battered among the Asset Classes
04:15PM  Johnson & Johnson Consumer Inc. Announces Completion of the Divestiture of SPLENDA® Brand to Heartland Food Products Group PR Newswire
10:24AM  5 U.S. Stocks Likely To Hike Their Dividends
09:30AM  Zacks Investment Ideas feature highlights: Johnson & Johnson, AT&T, Google, eBay and Amazon
Sep-24-15 01:15PM  This new idea could change recycling in the U.S. forever at Fortune
11:06AM  Apple's ad blocker impacts Walmart and Pope Francis weighs in on U.S. economy
10:06AM  Eli Lilly set for diabetes drug boost at Financial Times
09:04AM  Bull of the Day: Medivation (MDVN)
Sep-23-15 01:45PM  Volkswagen's clean-car image dirtied by emissions scandal
12:29PM  Walmart, Nike, Starbucks commit to 100% clean energy at Fortune
10:12AM  Top US businesses commit to renewable energy at CNBC
09:15AM  The Most Profitable Industries In 2015 at Forbes
09:06AM  Major companies join alliance seeking 100 pct green electricity
07:20AM  Cambridge biotech startup to focus on muscle diseases with first drug at
03:14AM  Bristol-Myers Squibbs Oncology Segment in 2Q15
03:14AM  How Did Bristol-Myers Squibbs Virology Segment Perform in 2Q15?
Sep-22-15 05:30PM  Recall stocks: Buying opportunities?
04:04PM  Starbucks, Nike join 100% renewable energy pledge AFP
02:52PM  J&J: No More Tears for Long-Suffering Investors at
02:07PM  Designing the Common Stock Portion of Your Retirement Portfolio: Concentrated or Diversified Part 3
07:54AM  Early movers: MSFT, DRI, GIS, AZO, JNJ, BAC & more at CNBC
07:00AM  For working mothers flextime, childcare, paid leave are key issues Reuters
Sep-21-15 07:01PM  Biotech stocks fall on Clinton vow to fight 'price gouging'
05:33PM  Stocks end higher, led by financial shares; drugmakers drop
04:35PM  What Was the Market Response to Sanofis 2Q15 Earnings?
11:22AM  5 Rocket Stocks to Buy Now at TheStreet
11:05AM  Bristol-Myers Squibbs Profitability and Financial Guidance
Sep-20-15 12:41PM  Are Big Pharma Stocks Grossly Overvalued? at Motley Fool
10:51AM  The 10 Most Valuable NFL Teams at TheStreet
Sep-18-15 04:35PM  TG Therapeutics Up on FDA Consent for Leukemia Study
03:13PM  Make The World A Better Place With...Stock Picks?
11:16AM  Advertisers leave The View amid Miss America controversy at Fortune
11:06AM  Biogen and Gilead Help Biotechnology Outperform
08:37AM  Eli Lilly (LLY) in Focus: Stock Jumps 6.6% in Session
07:50AM  Bearish On Bucks? Try This ETF
06:58AM  This Trillion-Dollar Portfolio Offers Double the Dividend Yield of the S&P 500 at Motley Fool
Sep-17-15 04:29PM  Study: Type 2 diabetes pill Jardiance cuts risk of death
02:08PM  Lilly Diabetes Drug Jardiance Cuts Death Rate By 32% at Investor's Business Daily
10:34AM  Stocks struggle for gains as Fed decision looms at CNBC
09:55AM  Achillion Pharma Rises on Solid Interim Results
Sep-16-15 04:40PM  GW Pharmaceuticals Up on Encouraging Schizophrenia Data
01:30PM  The Safest Stock To Own In Any Market
01:03PM  What will it take to get U.S. equities up on the year?
12:39PM  Groups seek details on Senate probe into painkiller ties
07:00AM  Funds That Channel Ben Graham at Morningstar
Sep-15-15 06:13PM  Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results PR Newswire
04:50PM  AbbVie Seeks FDA Approval for Imbruvica's Label Expansion
02:48PM  Colgate, Johnson & Johnson, Procter & Gamble -- Which Dividend Stock Is Best for You? at TheStreet
11:33AM  Bristol-Myers Squibb Stock Reacts Negatively to 2Q15 Earnings
10:08AM  What in the World Happened to XenoPort? at
05:48AM  Johnson & Johnson Primed for M&A at
Sep-14-15 12:41PM  Avoid these stocks if the Fed hikes rates: Goldman
11:07AM  How Will Vertex Solve Its Falling Revenue Woes?
10:19AM  Goldman: Here Are the Stocks to Own and Avoid When the Fed Is Hiking Rates at Bloomberg
Sep-13-15 02:34PM  Eight U.S. Corporate Giants Getting Battered By The Strong Buck at Forbes
08:01AM  3 Stocks Everyone in Their 60s Should Own at Motley Fool
Sep-12-15 12:01AM  The Wisdom of a Stock-Market Nonconformist at
Sep-11-15 03:10PM  The professional: J&J CEO Alex Gorsky plays it safe in Boston at
03:00PM  Johnson & Johnson CEO prescribes innovation for all that ails big pharma at
04:02AM  $2 Billion Club: A Look At Most Popular Vanguard ETFs at Investor's Business Daily
Sep-10-15 12:32PM  Estée Lauders 4Q15 Skincare Sales Disappoint the Most
11:52AM  With Volatile Markets, Here Are 16 Companies That Increased Dividends For Over 50 Consecutive Years at Forbes
07:05AM  The numbers dont lie: Apples stock is a bargain at MarketWatch
07:05AM  The numbers dont lie: Apples stock is a bargain
Sep-09-15 05:54PM  Tetraphase's (TTPH) Antibiotic Fails in Phase III Study
02:13PM  Cooper Companies Reported Mixed 2Q15 Results
12:22PM  Tetraphase Craters After Antibiotic Fails Trial at Investor's Business Daily
10:38AM  S&P 500 Index Futures Trading Higher
07:03AM  Does Achillion's 13% Slump in August Make It a Bargain? at Motley Fool
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PRINCE CHARLESDirectorAug 06Buy99.252,500248,13225,645Aug 10 12:49 PM
PRINCE CHARLESDirectorJun 02Buy99.222,500248,05023,145Jun 03 05:20 PM
Stoffels PaulusChief Scientific OfficerApr 28Option Exercise64.43228,68314,733,404281,723Apr 30 04:56 PM
Stoffels PaulusChief Scientific OfficerApr 28Sale100.73187,25018,862,14294,473Apr 30 04:56 PM
Fasolo PeterVP, Global Human ResourcesMar 05Option Exercise65.37115,3077,537,619147,895Mar 09 05:14 PM
Fasolo PeterVP, Global Human ResourcesMar 05Sale102.40115,30711,807,86332,588Mar 09 05:14 PM
Stoffels PaulusChief Scientific OfficerFeb 09Option Exercise0.0029,073064,647Feb 11 08:16 PM
Caruso Dominic JVP, Finance; CFOFeb 09Option Exercise0.0031,5370101,324Feb 11 08:16 PM
Fasolo PeterVP, Global Human ResourcesFeb 09Option Exercise0.0020,935042,109Feb 11 08:16 PM
Gorsky AlexChairman, CEOFeb 09Option Exercise0.0042,1120130,173Feb 11 08:17 PM
COSGROVE STEPHEN JCorporate ControllerJan 16Option Exercise0.0011,1080101,402Jan 21 05:48 PM
Ullmann Michael HVP, General CounselJan 16Option Exercise0.008,949075,628Jan 21 05:48 PM
Caruso Dominic JVP, Finance; CFOJan 16Option Exercise0.0012,615074,216Jan 21 05:48 PM
Gorsky AlexChairman, CEOJan 16Option Exercise0.0016,845094,425Jan 21 05:48 PM
Stoffels PaulusChief Scientific OfficerJan 16Option Exercise0.0011,629039,539Jan 21 05:48 PM
Fasolo PeterVP, Global Human ResourcesJan 16Option Exercise0.008,374024,336Jan 21 05:48 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,689031,210Dec 19 04:37 PM
JOHNSON & JOHNSON10% OwnerNov 12Buy18.0040,000720,0003,077,005Nov 12 03:06 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Option Exercise66.182,490164,78892,784Nov 07 04:49 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Sale108.552,490270,29390,294Nov 07 04:49 PM